Gilead Sciences (GILD) Competitors

Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Is AMGN or GILD a better dividend stock?

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 2.7%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 62.9% of its earnings in the form of a dividend. Amgen has increased its dividend for 14 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has stronger valuation and earnings, AMGN or GILD?

Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$33.42B	4.80	$4.09B	$12.23	24.36
Gilead Sciences	$28.75B	5.10	$480M	$5.02	23.55

Which has more risk and volatility, AMGN or GILD?

Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.

Do analysts prefer AMGN or GILD?

Amgen presently has a consensus price target of $309.42, indicating a potential upside of 3.86%. Gilead Sciences has a consensus price target of $118.08, indicating a potential downside of 0.11%. Given Amgen's higher possible upside, equities analysts clearly believe Amgen is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	1 Sell rating(s)	11 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.35
Gilead Sciences	0 Sell rating(s)	6 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.86

Is AMGN or GILD more profitable?

Gilead Sciences has a net margin of 21.86% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	18.96%	174.71%	13.12%
Gilead Sciences	21.86%	50.99%	17.24%

Do insiders & institutionals believe in AMGN or GILD?

76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.7% of Amgen shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media favor AMGN or GILD?

In the previous week, Amgen had 3 more articles in the media than Gilead Sciences. MarketBeat recorded 61 mentions for Amgen and 58 mentions for Gilead Sciences. Amgen's average media sentiment score of 1.34 beat Gilead Sciences' score of 1.17 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	47 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	41 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Amgen beats Gilead Sciences on 12 of the 20 factors compared between the two stocks.